Pegfilgrastim biosimilar - Tanvex Biopharma
Alternative Names: TX-04Latest Information Update: 28 Apr 2024
At a glance
- Originator Tanvex BioPharma
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Radioprotectives; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Neutropenia in USA
- 01 Mar 2021 Phase-I clinical trials in Neutropenia in USA (unspecified route) (Tanvex Biopharma pipeline, March 2021)